Pharmacotherapy developments in autophagy inhibitors for bladder cancer

Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1853-1860. doi: 10.1080/14656566.2023.2254697. Epub 2023 Sep 10.

Abstract

Introduction: Autophagy is an intracellular process that plays a key role in the cellular homeostasis. Recently, it has been described as a potential therapeutic target in oncology, whether by activating or inhibiting its different cascades. Autophagy inhibitors interact with different molecular processes of the hallmarks of cancer.

Areas covered: Multiple proteins of the autophagy cascade could be aimed by specific inhibitors in many tumors, notably bladder cancer. In fact, bladder cancer has been increasing in prevalence over the last decade, and resistance to conventional treatment has been extensively reported in the literature. Autophagy inhibitors in bladder cancer have been described in preclinical studies to increase the sensitivity of the tumor to chemotherapy and radiotherapy. This paper is a review of the literature, which selected randomized trials, cohort studies, and case-control studies documenting the relationship between autophagy inhibitors and bladder cancer treatment.

Expert opinion: Autophagy is a promising pathway for cancer cell targeting that opens the horizons for a potential new therapeutic area in particular the multidisciplinary management of bladder cancer.

Keywords: Autophagy inhibitors; Cancer therapy; bladder cancer; hallmarks of cancer; novel therapy.

Publication types

  • Review

MeSH terms

  • Autophagy
  • Humans
  • Urinary Bladder Neoplasms* / pathology